Spinal Cord Stimulator Paresthesia-Free Therapy 2026
Paresthesia-Free Spinal Cord Stimulation Patents
High-frequency sub-perception SCS has shifted implantable pain therapy away from tonic paresthesia-masking toward WDR neuron desensitization at 1.5–100 kHz. This dataset spans 60+ patent records across five assignees and six jurisdictions from 2013 to 2026.
How Frequency-Modulated SCS Eliminates Paresthesia
Paresthesia-free SCS delivers electrical signals predominantly in the 1.5–100 kHz range to the epidural space, modulating pain pathways in the dorsal horn without activating large-diameter sensory fibers. The mechanistic basis centers on desensitization of wide dynamic range (WDR) neurons, a concept articulated across the Nevro Corp. patent family describing how high-frequency signals deactivate hyperactive WDR cells independently of peripheral nerve inputs.
Three broad technical sub-domains are identifiable within this dataset: pure high-frequency paresthesia-free delivery (1.5–100 kHz continuous signals, exemplified by Nevro’s 10 kHz HF10 platform); frequency-modulated and multi-frequency hybrid architectures applying simultaneous or sequential low- and high-frequency signals across distinct spinal targets; and amplitude- and frequency-modulated transcutaneous approaches covered by the University of Southern California’s multi-channel patent family.
The innovation timeline spans 2013 to 2026. Nevro Corporation established foundational claims in 2013–2014 AU and US filings. A mid-stage maturation cluster from 2016–2020 added selective frequency switching and multi-frequency architectures, while Boston Scientific entered with frequency-distributed waveform delivery from 2018 onward. Biotronik filed a multi-modality SCS patent in 2018 (EP) combining sub-perception and paresthesia-based therapy types.
Among retrieved patent records, five identifiable assignees account for all filings in this dataset. Nevro Corp. holds approximately 40 records in this dataset, making it the most patent-active assignee retrieved, followed by Boston Scientific Neuromodulation Corporation and University of Southern California with approximately 8 records each in retrieved records.
Technology Cluster and Temporal Filing Patterns
Within this dataset, patent activity clusters into four technology groups and shows a clear acceleration in the 2023–2026 cohort toward evoked-potential guidance, dose reduction, and transcutaneous FM platforms.
Patent Records by Technology Cluster — Dataset Snapshot
High-frequency fixed-frequency paresthesia-free stimulation is the most patent-dense cluster in this dataset, with approximately 22 records, followed by multi-frequency hybrid architectures at approximately 14 records.
↗ Click bars to exploreFiling Activity by Era — Retrieved Records
The 2023–2026 cohort shows the highest concentration of emerging-direction filings in this dataset, with Boston Scientific’s evoked-potential and Nevro’s dose-reduction families both appearing in this period.
↗ Click bars to exploreKey Clinical Indications for Paresthesia-Free SCS Technology
Patent claims and clinical literature in this dataset span five distinct pain and rehabilitation indications, ranging from chronic back pain at T9–T10 to spinal cord injury sensory rehabilitation in tetraplegia patients.
Chronic Back Pain and FBSS
The primary application domain in this dataset, Nevro’s foundational patents explicitly target lumbar vertebral levels T9–T10 for back and leg pain relief in failed back surgery syndrome (FBSS) patients. Clinical literature from 2021 confirms HF10 therapy as a first-line programming option, and the 2020 MULTIWAVE study protocol compared tonic, burst, and HF waveforms specifically in FBSS patients. A 2015 clinical summary documents 10 kHz HF SCS outcomes across the Nevro platform.
Implantable SCSComplex Regional Pain Syndrome
Clinical trial data retrieved in this dataset includes a 2015 study protocol comparing 40 Hz, 500 Hz, 1,200 Hz, burst, and placebo specifically for CRPS. A 2020 sub-perception and supra-perception crossover trial enrolled both FBSS and CRPS patients, confirming 50% VAS reduction with 1 kHz stimulation. This evidence base supports frequency-modulated SCS as a viable CRPS treatment modality.
Sub-Perception SCSPeripheral and Diabetic Neuropathy
Nevro’s high-frequency stimulation platform has been explicitly extended to peripheral polyneuropathy (PPN) and painful diabetic neuropathy (PDN) through a series of continuation patents from 2018 through 2025 (US, AU) targeting somatosensory restoration at 1.5–100 kHz. A 2025 US filing specifically covers dysesthesia and motor deficit restoration. A separate 2025 US patent addresses sensory and motor deficits in patients with spinal cord injuries and peripheral polyneuropathy.
NeuromodulationSpinal Cord Injury Sensory Rehab
University of Washington holds NSF-funded patents (2023 and 2025 US) covering high-frequency epidural stimulation as a sensory interface specifically for sensation control in spinal cord injury patients, with focus on upper limb function restoration in tetraplegia — a distinct application not addressed by the chronic pain-focused Nevro or Boston Scientific patent families. These filings represent a separate rehabilitation engineering trajectory within this dataset.
SCI RehabilitationKey Patent Assignees in Paresthesia-Free SCS (Retrieved Records)
In this dataset, five assignees account for all retrieved patent records, with Nevro Corp. holding approximately 40 records in retrieved records — the largest single-assignee concentration — and Boston Scientific Neuromodulation Corporation filing a differentiated technical approach across approximately 8 records in this dataset.
Assignee Filing Counts — Paresthesia-Free SCS (Dataset Snapshot)
↗ Click bars to exploreNevro Corp.
Nevro Corp. holds approximately 40 patent records in this dataset across US and AU jurisdictions, spanning 2013 through 2025–2026, making it the most patent-active assignee in retrieved records. Core claims cover non-paresthesia-producing therapy signals at 1.5–100 kHz with no paresthesia mapping requirement, multi-frequency simultaneous delivery to distinct spinal targets, and the most recent 2024–2025 WO/US filings introducing dose-reduction and stimulation remission protocols. Multiple active US and AU grants remain enforced through the current filing period.
United StatesBoston Scientific Neuromodulation
Boston Scientific Neuromodulation Corporation holds approximately 8 patent records in this dataset across US, AU, WO, and EP jurisdictions, with filings from 2018 through 2026. Its technical approach is differentiated from Nevro’s: frequency-distributed waveforms spanning 0.001–20 kHz sustain paresthesia throughout therapy rather than eliminating it, and the 2024–2026 evoked synaptic potential (ESP) guidance family introduces closed-loop sub-perception programming without paresthesia feedback. A 2025 EP filing introduces paresthesia-guided sweet-spot targeting followed by sub-perception delivery at ≤130 Hz.
United StatesFour Strategic Frontiers in Paresthesia-Free SCS (2024–2026)
The 2024–2026 filing cohort in this dataset reveals four distinct technology directions: dose reduction and stimulation remission, evoked synaptic potential-guided closed-loop programming, transcutaneous FM/AM expansion, and sensory deficit restoration beyond pain.
Dose Reduction and Stimulation Remission Protocols
Nevro’s 2024–2025 WO and US filings introduce the concept of titrating paresthesia-free stimulation to reduced doses over time, leveraging the carry-over effect unique to sub-perception therapy. A 2025 WO filing introduces ‘remission’ framing — paresthesia-free stimulation inducing persistent pain relief that continues after signal cessation. This has direct implications for miniaturized implant design and externally powered device architectures.
Evoked Synaptic Potential-Guided Closed-Loop Programming
Boston Scientific’s 2024 WO and 2026 AU filings introduce evoked synaptic potential (ESP) sensing — distinct from previously established evoked compound action potential (ECAP) sensing — as a feedback signal to guide paresthesia-free stimulation programming. This enables closed-loop optimization without requiring patient-reported paresthesia as a surrogate, representing a differentiated trajectory in the competitive landscape. The 2026 AU filing is currently pending.
Nevro HF10 vs. Boston Scientific Frequency-Distributed Approach
Click any row to explore further.
| Dimension | Nevro Corp. (HF10 Platform) | Boston Scientific Neuromodulation |
|---|---|---|
| Core Mechanism | WDR neuron desensitization via continuous or duty-cycled signal at ~10 kHz; no paresthesia generated | Frequency-distributed waveforms (0.001–20 kHz) sustaining paresthesia throughout therapy duration |
| Frequency Range | 1.5–100 kHz (foundational claims); 10 kHz as primary commercial frequency | 0.001–20 kHz distributed across two frequency groups within a single session |
| Paresthesia Strategy | Sub-perception — paresthesia eliminated; no paresthesia mapping required for programming | Sustained paresthesia via frequency distribution; 2025 EP filing adds paresthesia-guided sweet-spot targeting transitioning to sub-perception at ≤130 Hz |
| Closed-Loop Feedback | Dose-reduction and remission protocols (2024–2025 WO/US); no ESP-based guidance in dataset | Evoked synaptic potential (ESP) sensing for closed-loop paresthesia-free programming (2024 WO, 2026 AU) |
| Primary Spinal Target | T9–T10 vertebral level for back and leg pain; extended to C2–C6 for cephalic/cervical pain | Not specified to vertebral level in retrieved records; therapy duration-based delivery |
| Patent Records in Dataset | ~40 records; US and AU primary jurisdictions; filings from 2013 through 2025–2026 | ~8 records; US, AU, WO, EP jurisdictions; filings from 2018 through 2026 |
| Earliest Filing | 2013 (AU, US) — foundational WDR desensitization mechanism | 2018 (US) — frequency-distributed waveform architecture |
| Indication Expansion | Peripheral polyneuropathy, PDN, spinal cord injury, sensory/motor deficit restoration (2018–2025) | Evoked potential guidance for sub-perception programming; lower-frequency sub-perception (2025 EP) |
Frequently Asked Questions: Paresthesia-Free SCS Patents
Based on retrieved patent records, paresthesia-free SCS is delivered predominantly in the 1.5–100 kHz range. Nevro’s foundational claims center on signals in this band, with 10 kHz as the primary commercial frequency. Boston Scientific’s frequency-distributed approach spans 0.001–20 kHz, while a 2025 EP filing describes sub-perception therapy at frequencies as low as ≤130 Hz achieved via paresthesia-guided sweet-spot targeting.
According to retrieved patent records from Nevro Corp., the mechanistic basis centers on desensitization of wide dynamic range (WDR) neurons in the dorsal horn. High-frequency signals at 1.5–100 kHz deactivate hyperactive WDR cells independently of peripheral nerve inputs, modulating pain pathways without activating the large-diameter sensory fibers that cause the characteristic tingling of conventional tonic SCS.
In this dataset, Nevro Corp. holds approximately 40 patent records across US and AU jurisdictions from 2013 through 2025–2026 — the largest concentration in retrieved records. Boston Scientific Neuromodulation Corporation and University of Southern California each hold approximately 8 records. University of Washington holds approximately 3 records, and Biotronik SE & Co. KG holds approximately 1 record in this dataset.
Retrieved patent records and clinical literature in this dataset cover five main indications: chronic back and leg pain at vertebral levels T9–T10 (including failed back surgery syndrome); complex regional pain syndrome (CRPS); peripheral polyneuropathy and painful diabetic neuropathy (PDN); spinal cord injury-related sensory and motor deficits; and cervical/cephalic pain addressed via C2–C6 epidural placement. The 2021 clinical literature review documents 10 kHz HF10 as a first-line programming option for chronic pain.
The 2024–2026 cohort in this dataset reveals four directions: (1) Nevro’s dose-reduction and stimulation remission protocols (2024–2025 WO/US) leveraging the carry-over effect of sub-perception therapy; (2) Boston Scientific’s evoked synaptic potential (ESP) guidance for closed-loop paresthesia-free programming (2024 WO, 2026 AU); (3) University of Southern California’s continued prosecution of transcutaneous FM/AM neuromodulation platforms through 2026; and (4) Nevro’s extension into somatosensory and motor deficit restoration (2024–2025 US/AU).
Based on this dataset, the United States is the largest single jurisdiction, hosting the bulk of Nevro and Boston Scientific active grants and pending applications. Australia is heavily utilized by both Nevro and USC as a secondary enforcement jurisdiction, with multiple active grants through 2025–2026. WO/PCT filings are used by USC (2020), Nevro (2024), and Boston Scientific (2024). Europe (EP) is represented by Biotronik (2018) and a Boston Scientific pending application (2025), and Canada has one pending USC application (2020).
Data and insights on this page are based on a limited patent and literature dataset and are for reference only. Figures may not represent the complete technology landscape.